Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
